(158 days)
The Sunrise Air is a non-invasive home care aid in the evaluation of obstructive sleep apnea (OSA) in patients 18 years and older with suspicions of sleep breathing disorders.
The Sunrise Air consists of the Sunrise software (v1.28.00), which analyzes data from one of three compatible sensors (Sunrise sensor 1, Sunrise sensor 2, or Sunrise Air) placed on the patient's chin. Sunrise sensor 1 was approved through DEN210015, while Sunrise sensor 2 was cleared through K222262. The current version of the Sunrise device introduces a new sensor, Sunrise Air. The Sunrise device is intended to detect respiratory events, identify sleep stages and position, and generate key sleep parameters—such as the apnea-hypopnea index ("Sunrise AHI") and positional states classifications. The collected data is compiled into a report for further interpretation by a healthcare provider.
The provided FDA 510(k) clearance letter for the Sunrise Air device primarily focuses on demonstrating substantial equivalence to a predicate device, rather than detailing a comprehensive clinical study to prove the device meets specific acceptance criteria for its claimed indications.
The document highlights bench testing for technical equivalence, but lacks the detailed clinical study information typically provided for direct performance claims against established ground truth. Specifically, it states that "No modifications have been made to the Sunrise algorithm used to generate sleep parameters," and that a "validation study of SpO₂ and pulse rate accuracy for the subject device was conducted using raw PPG data acquired during the clinical validation for the Sunrise sensor 2 (K222262)." This suggests reliance on prior clearances for core algorithm performance and a specific re-validation for only the PPG data processing change.
Therefore, many of the requested details about acceptance criteria, clinical study design, and ground truth establishment for the overall device performance (e.g., AHI calculation, OSA evaluation) are not explicitly present in this summary.
Given the information in the provided document, here's what can be extracted and inferred:
1. A table of acceptance criteria and the reported device performance:
Based on the information provided, the "acceptance criteria" are implied by the comparisons to the predicate and reference devices, and some specific performance metrics are given for SpO2 and pulse rate. The primary acceptance criterion for the device's main function (evaluation of OSA via AHI) is that "No modifications have been made to the Sunrise algorithm used to generate sleep parameters," implying continued equivalence to the predicate's performance.
| Performance Metric | Acceptance Criteria (Implied/Direct) | Reported Device Performance (Sunrise Air) |
|---|---|---|
| Overall Device Performance (OSA Evaluation) | Implied substantial equivalence to predicate device (Sunrise K222262) in the evaluation of OSA, as no changes were made to the core AHI algorithm. | "No modifications have been made to the Sunrise algorithm used to generate sleep parameters." The device generates "key sleep parameters—such as the apnea-hypopnea index ('Sunrise AHI')." |
| SpO₂ Accuracy | Not explicitly stated but inferred from previous predicate's clearance (K222262). Common standards are often <3.0% RMS. | 1.91% RMS over the range of 70-100% |
| Pulse Rate Accuracy | Not explicitly stated but inferred from previous predicate's clearance (K222262). Common standards are often within 5 bpm or <5% RMS. | 2.73 beats per minute (bpm) RMS for a claimed measurement range of 51 to 104 bpm |
| Accelerometer and Gyroscope Signals | Technical equivalence to predicate device. | Signals measured by subject and predicate devices found to be equivalent. |
| Thermistor Signal (Breathing Patterns) | Equivalent performance to oronasal thermal airflow sensor of reference device. | Equivalent performance in capturing breathing patterns demonstrated. |
| Microphone Signal (Snoring) | Comparable performance to microphone of reference device (Somno HD). | Comparable performance observed; sound patterns visually similar, synchronized transitions, comparable noise variations. |
Study that Proves the Device Meets Acceptance Criteria:
The document describes a combination of bench testing and reliance on prior clinical validation for specific components. There isn't a single, new "study" designed to prove the overall device meets a set of clinical acceptance criteria for OSA evaluation, but rather, individual tests to establish equivalence of components or re-validate specific algorithm changes.
2. Sample size used for the test set and the data provenance:
- Overall Device (for AHI/OSA evaluation): Not explicitly stated for a new study. The document states that "No modifications have been made to the Sunrise algorithm used to generate sleep parameters." This implies reliance on the clinical validation data from the predicate device (Sunrise K222262). The original K222262 submission would contain this information.
- SpO₂ and Pulse Rate Accuracy:
- Sample Size: Not explicitly stated. The study was conducted using "raw PPG data acquired during the clinical validation for the Sunrise sensor 2 (K222262)." The sample size for that original clinical validation would be the relevant number.
- Data Provenance: Retrospective, as it used data from a previous clinical validation study (for Sunrise sensor 2, cleared under K222262). The country/region of origin of this data is not specified in this document.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Overall Device (for AHI/OSA evaluation): Not specified in this document, as the core algorithm relies on prior validation. For the original K222262 clearance, ground truth would typically be established by a consensus of sleep experts (e.g., board-certified sleep physicians or registered polysomnographic technologists (RPSGTs)).
- SpO₂ and Pulse Rate: Ground truth for these parameters is typically established through a co-oximeter or arterial blood gas analysis, not necessarily by "experts" in the human sense, but by a gold-standard measurement device.
4. Adjudication method (e.g., 2+1, 3+1, none) for the test set:
- Not specified within this 510(k) summary for any new studies. For the original clinical validation of the AHI algorithm, an adjudication method (such as independent scoring by multiple qualified technologists/physicians with consensus or a tie-breaker) would typically be employed for the polysomnography (PSG) ground truth.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, an MRMC comparative effectiveness study involving human readers and AI assistance is not described in this document. The device is for "aiding in the evaluation" and generates parameters; it is not presented as an AI-assisted diagnostic tool for human interpretation improvement in this summary.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:
- Yes, the device's capability to "detect respiratory events, identify sleep stages and position, and generate key sleep parameters" and a "Sunrise AHI" implies a standalone algorithmic performance in generating these outputs from the sensor data. The statement "No modifications have been made to the Sunrise algorithm used to generate sleep parameters" means that the standalone performance of the algorithm itself is considered validated based on its prior clearance. The SpO₂ and pulse rate accuracy also represent standalone algorithm performance.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- Overall Device (for AHI/OSA evaluation): Not explicitly stated, but for sleep apnea diagnostic devices, the ground truth is overwhelmingly polysomnography (PSG) scored by qualified experts (e.g., according to AASM guidelines). This would have been the ground truth for the predicate device's (K222262) clearance.
- SpO₂ and Pulse Rate: The ground truth for SpO₂ accuracy is typically established using a reference pulse oximeter or co-oximeter (invasive arterial blood gas analysis may be used for a subset of the data if required for the specific accuracy claims and range). For pulse rate, a simultaneous ECG or the reference oximeter's heart rate measurement.
8. The sample size for the training set:
- Not specified in this document. As the core algorithm is unchanged from the predicate, its training data would have been part of the K222262 submission.
- The document mentions "cloud-based algorithm (Sunrise PPG algorithm)" as a change for PPG data processing, but it does not specify the training set size for this particular component, only that its validation was done on existing test data.
9. How the ground truth for the training set was established:
- Not specified in this document, as the core algorithm leverages prior clearance. For the predicate device, ground truth for training data would have broadly been established in the same manner as the test set: expert-scored polysomnography (PSG) data. However, the specific details (e.g., single expert vs. consensus) are not provided here.
FDA 510(k) Clearance Letter - Sunrise Air
Page 1
U.S. Food & Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993
www.fda.gov
Doc ID # 04017.08.00
August 29, 2025
Sunrise SA
Grégoire Lejeune
Hardware Manager
Chaussée de Marche, 598/02
Namur, 5101
Belgium
Re: K250874
Trade/Device Name: Sunrise Air
Regulation Number: 21 CFR 868.2376
Regulation Name: Device For Sleep Apnea Testing Based On Mandibular Movement
Regulatory Class: Class II
Product Code: QRS
Dated: March 24, 2025
Received: August 1, 2025
Dear Grégoire Lejeune:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Page 2
K250874 - Grégoire Lejeune Page 2
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
Page 3
K250874 - Grégoire Lejeune Page 3
assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Rachana Visaria -S
Rachana Visaria, Ph.D.
Assistant Director
DHT1C: Division of Anesthesia,
Respiratory, and Sleep Devices
OHT1: Office of Ophthalmic, Anesthesia,
Respiratory, ENT, and Dental Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
Enclosure
Page 4
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Indications for Use
Form Approved: OMB No. 0910-0120
Expiration Date: 07/31/2026
See PRA Statement below.
510(k) Number (if known): K250874
Device Name: Sunrise Air
Indications for Use (Describe):
The Sunrise Air is a non-invasive home care aid in the evaluation of obstructive sleep apnea (OSA) in patients 18 years and older with suspicions of sleep breathing disorders.
Type of Use (Select one or both, as applicable):
☒ Prescription Use (Part 21 CFR 801 Subpart D)
☐ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number"
FORM FDA 3881 (8/23) Page 1 of 1 PSC Publishing Services (301) 443-6740 EF
Page 5
510(K) SUMMARY
1. SUBMITTER
Sunrise SA
Chaussée de Marche 598/02
5101 Namur
Belgium
Phone: +32 81 26 11 26
Contact Person: Grégoire Lejeune
Date Prepared: August 29, 2025
2. DEVICE
Name of Device: Sunrise Air
Common or Usual Name: Sleep apnea testing
Classification Name: Device for sleep apnea testing based on mandibular movement
Regulatory Class: II
Product Code: QRS
Regulation: 21 CFR 868.2376
Classification Panel: Anesthesiology
3. PREDICATE DEVICE
Predicate Device: Sunrise (K222262)
Reference Device: SOMNOscreen plus (K201054)
4. DEVICE DESCRIPTION
The Sunrise Air consists of the Sunrise software (v1.28.00), which analyzes data from one of three compatible sensors (Sunrise sensor 1, Sunrise sensor 2, or Sunrise Air) placed on the patient's chin. Sunrise sensor 1 was approved through DEN210015, while Sunrise sensor 2 was cleared through K222262. The current version of the Sunrise device introduces a new sensor, Sunrise Air. The Sunrise device is intended to detect respiratory events, identify sleep stages and position, and generate key sleep parameters—such as the apnea-hypopnea index ("Sunrise AHI") and positional states classifications. The collected data is compiled into a report for further interpretation by a healthcare provider.
Page 6
5. INDICATIONS FOR USE
The Sunrise Air is a non-invasive home care aid in the evaluation of obstructive sleep apnea (OSA) in patients 18 years and older with suspicions of sleep breathing disorders.
6. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
The Sunrise software, cleared under 510(k) K222262, is now compatible with an additional accessory: the Sunrise Air. The Sunrise algorithm—a component of the Sunrise software—has been updated to process raw data acquired by the optical module in both the Sunrise sensor 2 and the Sunrise Air.
The Sunrise Air retains the same features as the Sunrise sensor 2, with the following enhancements:
- Addition of a microphone;
- Integration of a rechargeable battery.
| Item | Subject device Sunrise Air | Predicate device Sunrise (K222262) | Reference device SOMNOscreen plus (K201054) | Comparison |
|---|---|---|---|---|
| Classification product code Subsequent product code | QRS | QRS | OLV MNR | Same as predicate device |
| Intended use/indications for use | The Sunrise Air is a non-invasive home care aid in the evaluation of obstructive sleep apnea (OSA) in patients 18 years and older with suspicions of sleep breathing disorders. | The Sunrise device is a non-invasive home care aid in the evaluation of obstructive sleep apnea (OSA) in patients 18 years and older with suspicions of sleep breathing disorders. | The SOMNOscreen plus is indicated for use in the recording, displaying, monitoring, printing, and storage of biophysical parameters for the purpose of assisting in the diagnosis of Neurological and Sleep Disorders. The device is a non-life-supporting physiological signal recording device intended to be used for studies testing adults and children/adolescents suspected of having sleep-related breathing disorders. This device is NOT | Same as predicate device |
Page 7
| Item | Subject device Sunrise Air | Predicate device Sunrise (K222262) | Reference device SOMNOscreen plus (K201054) | Comparison |
|---|---|---|---|---|
| designed to be used in a Life Support situation. This device is not designed for use on patients with cardiac pacemakers. | ||||
| Target population | 18 years and older | 18 years and older | 2 years and older | Same as predicate device |
| Type of use | Prescription | Prescription | Prescription | Same as predicate device |
| Intended use environment | Clinical or home | Clinical or home | Clinical or home | Same as predicate device |
| Wearable location | Chin | Chin | Multiple locations | Same as predicate device |
| Hardware components | Accelerometer, gyroscope Optical module, thermistor (Sunrise sensor 2 and Sunrise Air) Microphone (Sunrise Air) | Accelerometer, gyroscope Optical module, thermistor (Sunrise sensor 2) | Multiple components including microphone | Same as predicate device for accelerometer, gyroscope, optical module, and thermistor, same as reference device for microphone |
| Channels | Mandibular jaw movements, movement, position, respiratory effort Airflow, photoplethysmography, pulse rate, oxygen saturation (Sunrise sensor 2 and Sunrise Air) Snore (Sunrise Air) | Mandibular jaw movements, movement, position, respiratory effort Airflow, photoplethysmography, pulse rate, oxygen saturation (Sunrise sensor 2) | Multiple channels including snore | Same as predicate device for mandibular jaw movements, movement, position, respiratory effort, airflow, photoplethysmography, pulse rate, and oxygen saturation, same as reference device for snore |
| Size and weight | 42x17x6mm - 3g (Sunrise sensor 1) 40x22x12mm - 8g (Sunrise sensor 2) 44x20x8mm - 15g (Sunrise Air) | 42x17x6mm - 3g (Sunrise sensor 1) 40x22x12mm - 8g (Sunrise sensor 2) | Multiple sizes and weights | Same as predicate device (Sunrise sensor 1 and Sunrise sensor 2) Substantially equivalent to predicate device (Sunrise Air) |
| Raw data recording | Streamed to smartphone (Sunrise sensor 1) or on-board memory (Sunrise sensor 2 and Sunrise Air) | Streamed to smartphone (Sunrise sensor 1) or on-board memory (Sunrise sensor 2) | Streamed to computer or on-board memory | Same as predicate device |
| Power supply | Non-rechargeable lithium coin battery | Non-rechargeable lithium coin battery | Rechargeable lithium-ion battery | Same as predicate device (Sunrise |
Page 8
| Item | Subject device Sunrise Air | Predicate device Sunrise (K222262) | Reference device SOMNOscreen plus (K201054) | Comparison |
|---|---|---|---|---|
| (Sunrise sensor 1 and Sunrise sensor 2) or rechargeable lithium-ion battery with ~500 charging cycles (Sunrise Air) | with ~500 charging cycles | sensor 1 and Sunrise sensor 2) Same as reference device (Sunrise Air) | ||
| User interface | Smartphone and computer | Smartphone and computer | Computer | Same as predicate device |
| Patient contact type | In contact with intact skin surfaces for prolonged duration | In contact with intact skin surfaces for limited duration | In contact with intact skin surfaces for limited duration | Same contact type as predicate device, longer duration due to potential for repeated applications |
| Wearable software | Firmware is limited to control the recording and communications processes | Firmware is limited to control the recording and communications processes | Firmware is limited to control the recording and communications processes | Same as predicate device |
| Analysis software | Analysis performed off the recording device, exclusively cloud-based, by the proprietary software | Analysis performed off the recording device, exclusively cloud-based, by the proprietary software | Analysis performed off the recording by the proprietary software | Same as predicate device |
| Sterility | Non-sterile | Non-sterile | Non-sterile | Same as predicate device |
| Parameters | TST, wake and light/deep/REM sleep, SOL, WASO, SE, awakening index, ArI, REM sleep latency, AHI, ORDI, RDI, OAHI, CAHI, RERA index, RE, sleep time in supine and non-supine positions Oxygen saturation and pulse rate statistics (Sunrise sensor 2 and Sunrise Air) Snore statistics (Sunrise Air) | TST, wake and light/deep/REM sleep, SOL, WASO, SE, awakening index, ArI, REM sleep latency, AHI, ORDI, RDI, OAHI, CAHI, RERA index, RE, sleep time in supine and non-supine positions Oxygen saturation and pulse rate statistics (Sunrise sensor 2) | Multiple parameters including snore statistics | Same as predicate device, same as reference device for snore statistics |
| Pulse rate accuracy and measurement range | Accuracy (rms value) was found to be 2.73 beats per minute (bpm) for a claimed measurement range | Accuracy (rms value) was found to be 1.95 beats per minute (bpm) for a claimed measurement range | Claimed measurement range of 18 to 300 beats per minute (bpm) | Substantially equivalent to predicate device |
Page 9
| Item | Subject device Sunrise Air | Predicate device Sunrise (K222262) | Reference device SOMNOscreen plus (K201054) | Comparison |
|---|---|---|---|---|
| of 51 to 104 bpm (Sunrise sensor 2 and Sunrise Air) | of 51 to 104 bpm (Sunrise sensor 2) | |||
| Means of attachment | Adhesives | Adhesives | Multiple means | Same as predicate device |
7. PERFORMANCE DATA
The following performance data were provided in support of the substantial equivalence determination.
Biocompatibility
The device includes three patient-contacting components that come into contact with the skin on the patient's chin during the sleep study: the housing, the optical module window, and the double-sided adhesive. The device is intended for prolonged surface contact with intact skin. A biocompatibility evaluation was conducted in accordance with the FDA guidance document Use of International Standard ISO 10993-1, "Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing Within a Risk Management Process."
Software and Cybersecurity
The device has a moderate level of concern software component. Software verification and validation testing were conducted as recommended by the FDA guidance document Content of Premarket Submissions for Device Software Functions. Additionally, documentation was provided in accordance with the FDA guidance Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions to demonstrate that appropriate cybersecurity measures have been implemented and will be monitored and updated throughout the device's life cycle.
Electrical Safety and Electromagnetic Compatibility (EMC)
Electrical safety and EMC testing were conducted on the device to demonstrate compliance with the following standards: IEC 60601-1 for basic safety, IEC 60601-1-2 for electromagnetic compatibility, and IEC 60601-1-11 for use in the home healthcare environment. Documentation was provided in accordance with the FDA guidance document Electromagnetic Compatibility (EMC) of Medical Devices.
Bench Testing
Bench testing was conducted to demonstrate technical equivalence between the subject device, the predicate device, and the reference device. The signals measured by the accelerometer and gyroscope of the subject and predicate devices were compared, and their performance was found to be equivalent. No modifications have been made to the Sunrise algorithm used to generate sleep parameters.
Page 10
The signal measured by the thermistor of the subject device was compared to that of the oronasal thermal airflow sensor of the reference device, demonstrating equivalent performance in capturing breathing patterns. The signal measured by the microphone of the subject device was compared to that of the microphone of the reference device (Somno HD), with comparable performance observed. During both no-snoring and snoring situations, the sound patterns were visually similar between the two devices, with synchronized transitions from no-snoring to snoring phases and comparable noise variations when snoring was present.
While raw PPG data acquisition remains identical between the Sunrise Air and the previously cleared version of the Sunrise device, PPG data processing was moved from an embedded algorithm on the sensor to a cloud-based algorithm (Sunrise PPG algorithm) Therefore, a validation study of SpO₂ and pulse rate accuracy for the subject device was conducted using raw PPG data acquired during the clinical validation for the Sunrise sensor 2 (K222262) which has the same interface window, optical module, and application site. The SpO2 accuracy (rms value) was found to be 1.91% over the range of 70-100%. The pulse rate accuracy (rms value) was found to be 2.73 beats per minute (bpm) for a claimed measurement range of 51 to 104 bpm.
8. CONCLUSION
Based on the performance data, the Sunrise Air is as safe and effective as the predicate device and performs equivalently. Therefore, the Sunrise Air is substantially equivalent to the predicate device.
N/A